Xylem (NYSE:XYL) affirms Q3 Adj EPS guidance from $1.42-$1.47 to $1.42-$1.47 vs $1.46 analyst estimate. Affirms Q3 sales outlook from $2.300 billion to $2.300 billion vs $2.316 billion estimate.